Sorriso Pharmaceuticals

Founded in 2020 and based in San Diego, California, Sorriso Pharmaceuticals is a biotechnology company dedicated to developing disease-modifying antibodies for the treatment of inflammatory diseases such as Crohn’s disease and ulcerative colitis. The company's core mission is to transform antibody therapy by creating potent, orally deliverable antibodies that maintain their activity throughout the intestinal system. Sorriso's innovative platform addresses unmet needs in immune-mediated diseases, aiming to provide more effective and convenient treatment options.

Sorriso Pharmaceuticals has attracted significant attention and investment, securing funding to advance its research and development efforts. The company has made notable progress, including dosing the first patients in Phase 1b clinical trials for ulcerative colitis. With a strong leadership team and board of directors, Sorriso is poised to make a substantial impact on the treatment landscape for inflammatory diseases, potentially improving the quality of life for millions of patients worldwide.